LH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Labcorp Holdings Inc (LH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and discounted valuation relative to peers make it a compelling choice. While there are no immediate trading signals or recent news catalysts, the long-term growth potential and stability in the healthcare services sector support the investment decision.
The technical indicators are neutral with no strong signals. The MACD is slightly negative but contracting, RSI is neutral at 54.634, and moving averages are converging. Key support is at 261.967, and resistance is at 271.107. The stock is trading near its pivot point at 266.537, suggesting limited downside risk in the short term.
Strong Q3 financial performance with revenue up 8.58% YoY, net income up 54.22% YoY, and EPS up 55.22% YoY.
Positive analyst sentiment with multiple price target increases, including JPMorgan's $330 target and Morgan Stanley's $308 target, highlighting the stock's discounted valuation relative to peers.
The healthcare services sector is considered a 'safe haven' by analysts.
Hedge funds are selling the stock, with a significant increase in selling activity (676.52% over the last quarter).
No recent news or event-driven catalysts to drive short-term price movements.
Technical indicators are neutral, providing no strong entry signals.
Labcorp's Q3 2025 financials show robust growth: Revenue increased to $3.56 billion (up 8.58% YoY), net income rose to $261.1 million (up 54.22% YoY), EPS increased to $3.12 (up 55.22% YoY), and gross margin improved to 26.82% (up 4.68% YoY). These metrics indicate strong operational performance and profitability.
Analysts are generally positive on Labcorp. JPMorgan, Baird, and Morgan Stanley have raised price targets to $330, $326, and $308, respectively, citing strong Q4 results and the stock's discounted valuation relative to peers. Piper Sandler raised its target to $300 but maintained a Neutral rating.
